Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of a significant decline in short interest during the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a decline of 6.1% from the November 28th total of 3,620,000 shares. Based on an average daily trading volume, of 1,000,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 9.9% of the company’s stock are sold short.

Shares of NASDAQ:CRSP opened at $59.44 on Friday. The company’s fifty day moving average is $65.98 and its two-hundred day moving average is $51.14. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a 12-month low of $28.95 and a 12-month high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, equities research analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.

CRSP has been the subject of several analyst reports. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Needham & Company LLC restated a “buy” rating and issued a $84.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Roth Capital upped their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. Finally, Oppenheimer upped their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics presently has an average rating of “Buy” and an average target price of $71.38.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of CRSP. NEXT Financial Group Inc boosted its holdings in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares in the last quarter. Coastal Investment Advisors Inc. bought a new stake in Crispr Therapeutics in the third quarter worth $26,000. US Bancorp DE boosted its holdings in Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares during the period. BSW Wealth Partners bought a new stake in Crispr Therapeutics during the second quarter valued at about $39,000. Finally, BNP Paribas Arbitrage SA bought a new stake in Crispr Therapeutics during the second quarter valued at about $41,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: What are economic reports?



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link